, Uberti, J. Introduction: Many patients (pts) who are eligible for ASCT are unable to collect a minimum number of CD34 + stem cells to support high dose chemotherapy and ASCT. Plerixafor, a CXCR4 antagonist, in combination with G-CSF mobilizes more CD34+ stem cells when compared to G-CSF alone. Due to its cost, we commenced a risk adapted approach to the utilization of plerixafor for stem cell mobilization in pts undergoing ASCT. Our goal was to add plerixafor in pts who had ineffective mobilization thereby preventing mobilization failures. Re-mobilization results in added costs, delays with possible disease progression and time lost for the pts. Methods: The study was restricted to pts mobilized with 10 mcg/kg/day GCSF alone. There were two patient populations: those who had plerixafor added in the evening of day 5 if PB CD 34\ 10/L with apheresis commencing the following morning; and those who during apheresis had a daily collection yield of\ 0.5 Â 10 6 CD34/kg. Morning administration of G-CSF and evening dosing of plerixafor continued daily until apheresis was complete. Results: From February to July 2009, 147 mobilization attempts occurred with G-CSF alone (Myeloma 61, NHL 54, Amyloid 17, Hodgkin 10, POEMS 4 and 1 solid tumor). Median CD34 yield: 5.5 Â 10 6 CD34/kg; median apheresis 3. 67 pts (46%) received plerixafor; 37 during mobilization and 30 during collections. Overall, 7 of 147 (5%) failed to achieve a minimum of 2 Â 10 6 CD34/kg compared to a prior 22% failure rate. Day 4 PB CD34 count and day 1 apheresis yield were analyzed to predict who would require plerixafor under these guidelines (Table 1) . 72% of pts whose PB CD34\10 on day 4 received plerixafor vs 10% if $10. 110 pts did not start plerixafor prior to day 1 collection; if day 1 apheresis yield was \1.5, 76% subsequently received plerixafor. Conclusions: Implementing this risk adapted approach allows poor mobilizers to be identified promptly and for initiation of plerixafor during mobilization and collection, thereby reducing the number of failures. In pts whose PB CD34\ 10 on day 4 of G-CSF or whose day 1 yield is \1.5 x10 6 CD34/kg, earlier addition of plerixafor may result in fewer apheresis days. Based on this data, we are implementing the earlier addition of plerixafor. This risk adapted approach with early implementation of plerixafor may be more cost effective than waiting for failure 
